Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $1.32 in the prior trading day, Pyxis Oncology Inc (NASDAQ: PYXS) closed at $1.34, up 1.52%. In other words, the price has increased by $1.52 from its previous closing price. On the day, 1.33 million shares were traded. PYXS stock price reached its highest trading level at $1.43 during the session, while it also had its lowest trading level at $1.29.
Ratios:
Our goal is to gain a better understanding of PYXS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 83104256 and an Enterprise Value of 13622301. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.47 while its Price-to-Book (P/B) ratio in mrq is 0.95. Its current Enterprise Value per Revenue stands at 4.831 whereas that against EBITDA is -0.169.
Stock Price History:
The Beta on a monthly basis for PYXS is 1.12, which has changed by -0.648294 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 15.15%, while the 200-Day Moving Average is calculated to be -9.00%.
Shares Statistics:
The stock has traded on average 518.74K shares per day over the past 3-months and 663010 shares per day over the last 10 days, according to various share statistics. A total of 62.02M shares are outstanding, with a floating share count of 44.14M. Insiders hold about 28.82% of the company’s shares, while institutions hold 33.02% stake in the company. Shares short for PYXS as of 1753920000 were 4695721 with a Short Ratio of 9.05, compared to 1751241600 on 5064919. Therefore, it implies a Short% of Shares Outstanding of 4695721 and a Short% of Float of 9.1800004.
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.26 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.22 and -$1.42 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$1.16, with 6.0 analysts recommending between -$0.78 and -$1.42.
